Free Trial
NASDAQ:LONA

Athira Pharma Q2 2025 Earnings Results & Report

Athira Pharma logo
$3.23 -0.24 (-6.92%)
As of 03:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Athira Pharma met analyst earnings expectations in its Q2 2025 results, released August 7, 2025. The company reported EPS of -$1.80 versus the -$1.80 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Athira Pharma EPS Results

Actual EPS
-$1.80
Consensus EPS
-$1.80
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Athira Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Athira Pharma Q2 2025 Earnings FAQ

Athira Pharma (NASDAQ:LONA) reported earnings of -$1.80 per share for Q2 2025, matching the consensus estimate of -$1.80. The report was announced on Thursday, August 7, 2025.

Athira Pharma Earnings Headlines

Buy Stocks… A Crash is Coming
Think stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years.tc pixel
See More Athira Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Athira Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Athira Pharma and other key companies, straight to your email.

About Athira Pharma

Athira Pharma (NASDAQ:LONA) is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair.

The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis. These were development-stage candidates, not approved medicines.

Athira was founded in 2011 and advanced its programs through clinical research. Fosgonimeton did not meet the primary endpoints in a Phase 3 Alzheimer’s disease study, and the company subsequently reassessed its development plans.

View Athira Pharma Profile